First published in the Government *Gazette*, Electronic Edition, on 1 June 2022 at 5 pm.

No. S 452

HEALTH PRODUCTS ACT 2007

HEALTH PRODUCTS (CLINICAL RESEARCH MATERIALS) (AMENDMENT) REGULATIONS 2022

In exercise of the powers conferred by sections 71 and 72 of the Health Products Act 2007, the Health Sciences Authority, with the approval of the Minister for Health, makes the following Regulations:

Citation and commencement

1. These Regulations are the Health Products (Clinical Research Materials) (Amendment) Regulations 2022 and come into operation on 1 July 2022.

Amendment of regulation 2

2. In regulation 2(1) of the Health Products (Clinical Research Materials) Regulations 2016 (G.N. No. S 332/2016) (called in these Regulations the principal Regulations), after the definition of "regulated clinical trial", insert —

> " "relevant fee" means a fee specified in the Second Schedule to the Health Products (Fees) Regulations 2022 (G.N. No. S 450/2022);".

Deletion of First Schedule

3. Delete the First Schedule to the principal Regulations.

Miscellaneous amendments

4. In the principal Regulations —

(*a*) in the following provisions, delete "specified in the First Schedule":

Regulation 5(2)(*c*)

Regulation 6(3)(*c*)

Regulation 21(3)(*b*)

Regulation 22(3)(*b*); and

(*b*) in the following provisions, delete "and the First Schedule":

Regulation 21(4)

Regulation 22(4).

[G.N. Nos. S 94/2019; S 108/2021; S 730/2021; S 1078/2021]

Made on 25 May 2022.

BENJAMIN ONG
Chairperson,
Health Sciences Authority,
Singapore.

[401:04/01-000; AG/LEGIS/SL/122D/2020/10 Vol. 1]

(To be presented to Parliament under section 72(5) of the Health Products Act 2007).